Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03769103
Title Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors British Columbia Cancer Agency
Age Groups: adult | senior
Covered Countries CAN

No variant requirements are available.